Talazoparib
- Generic Name
- Talazoparib
- Brand Names
- Talzenna
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F2N6O
- CAS Number
- 1207456-01-6
- Unique Ingredient Identifier
- 9QHX048FRV
- Background
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...
- Indication
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...
- Associated Conditions
- HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Associated Therapies
- -
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
- Conditions
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT04846478
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Telaglenastat + Talazoparib In Prostate Cancer
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04824937
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 3
- Registration Number
- NCT04801966
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Talazoparib Maintenance Therapy in Triple-negative Breast Cancer
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 206
- Registration Number
- NCT04755868
- Locations
- 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 33
- Registration Number
- NCT04740190
- Locations
- 🇭🇰
Department of Clinical Oncology, Hong Kong, Hong Kong
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT04734730
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04703920
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Mylin A. Torres, MD
- Target Recruit Count
- 1
- Registration Number
- NCT04690855
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT04635631
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.